MMP-9 Inhibitor I

Name: MMP-9 Inhibitor I
Brand: TargetMol
SKU: T37726
Price: 118 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Synonyms:

Catalog No. T37726 Copy Product Info

🥰Excellent

MMP-9 Inhibitor I is an inhibitor of matrix metalloproteinase-9 (MMP-9) that is selective over MMP-1 and MMP-13 (IC50s = 5, 1,050, and 113 nM, respectively). MMP-9 Inhibitor I also decreases activity of TNF-α converting enzyme (TACE) in a dose-dependent manner (IC50 = 0.54 μM). MMP-9 Inhibitor I decreases TNF-α secretion stimulated by LPS in BV-2 microglial cells at concentrations of 50 and 100 μM. MMP-9 Inhibitor I is therefore used in neuroinflammatory and extracellular matrix regulation research to investigate metalloproteinase selectivity, cytokine shedding pathways, and microglial activation responses in cellular inflammation models.

Cas No. 206549-55-5

Pack Size	Price	USA Stock	Global Stock	Quantity
500 µg	$118	-	In Stock
1 mg	$189	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Appearance:Solid

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	MMP-9 Inhibitor I is an inhibitor of matrix metalloproteinase-9 (MMP-9) that is selective over MMP-1 and MMP-13 (IC50s = 5, 1,050, and 113 nM, respectively). MMP-9 Inhibitor I also decreases activity of TNF-α converting enzyme (TACE) in a dose-dependent manner (IC50 = 0.54 μM). MMP-9 Inhibitor I decreases TNF-α secretion stimulated by LPS in BV-2 microglial cells at concentrations of 50 and 100 μM. MMP-9 Inhibitor I is therefore used in neuroinflammatory and extracellular matrix regulation research to investigate metalloproteinase selectivity, cytokine shedding pathways, and microglial activation responses in cellular inflammation models.
Targets & IC50	MMP9:80 nM, TACE:0.54 μM
In vitro	Methods：Cells and recombinant proteins were treated with MMP-9 Inhibitor I at different concentrations. Its effects on inflammatory factor secretion as well as the activities of TACE and MMP-9 were detected. Results： 1.Treatment with 1–100 μM MMP-9 Inhibitor I for 1 hour inhibited LPS-induced TNF-α secretion in mouse BV2 microglia in a dose-dependent manner. 2.MMP-9 Inhibitor I at 0.1–1 μM suppressed the activity of recombinant human TACE, with an IC₅₀ value of 0.54 μM. 3.After 1-hour treatment with 80 nM MMP-9 Inhibitor I, the cleavage of pro-TNF-α peptide (residues 71–82) by recombinant MMP-9 was specifically blocked [1].

Chemical Properties

Molecular Weight	511.63
Formula	C₂₇H₃₃N₃O₅S
Cas No.	206549-55-5
Smiles	O=C(NO)C1=CC(=CC(=C1N(CC=2C=CC=CC2)S(=O)(=O)C3=CC=C(OC)C=C3)C)CN(CC)CC

Storage & Solubility Information

Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMF: 20 mg/mL (39.09 mM), Sonication is recommended. DMSO: 80 mg/mL (156.36 mM), Sonication is recommended. Ethanol: 33 mg/mL (64.5 mM), Sonication is recommended. Ethanol:PBS (pH 7.2) (1:8): 0.11 mg/mL (0.21 mM), Sonication is recommended.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc